These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37497733)

  • 1. The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort.
    Ruscitti P; Pantano I; Perrotta FM; Celletti E; Volpe P; Ciliento MS; Marino V; Raimondi M; Gaggiano E; Mauro D; Cataldi G; Italiano N; Di Muzio C; Navarini L; Zicolella R; Gabini M; Cipollone F; Lubrano E; Giacomelli R; Ciccia F; Cipriani P
    Clin Exp Rheumatol; 2024 Jan; 42(1):69-76. PubMed ID: 37497733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort.
    Ramonda R; Lorenzin M; Chimenti MS; Atzeni F; Semeraro A; D'Angelo S; Selmi C; Ortolan A; Marchesoni A; Manara M; Luchetti Gentiloni MM; Santo L; Salvarani C; Cauli A; Rossini M; Amato G; Cozzi G; Scagnellato L; Ferraioli M; Carriero A; Fracassi E; Giorgio F; Doria A; Foti R; Carletto A;
    Arthritis Res Ther; 2024 Sep; 26(1):172. PubMed ID: 39342310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre "Real-Life" Cohort Study.
    Ruscitti P; Cataldi G; Gentile M; Dionisi A; Volpe P; Finucci A; Verardi L; Di Muzio C; Italiano N; Celletti E; Di Penta M; Di Cola I; Marrelli A; Alfonsi A; Delle Monache F; Cipollone F; Gabini M; Cipriani P
    Rheumatol Ther; 2024 Jun; 11(3):539-551. PubMed ID: 38436915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.
    Ramonda R; Lorenzin M; Carriero A; Chimenti MS; Scarpa R; Marchesoni A; Lubrano di Scorpaniello E; Salvarani C; Cauli A; Semeraro A; Santo L; Ortolan A; Doria A; Fracassi E; Virelli G; Masia M; Fanizzi R; Visalli E; Amato G; Carletto A; Foti R;
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33593933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of psoriatic arthritis with secukinumab: a case series.
    Nicola S; Rolla G; Monti R; Brussino L
    J Dermatolog Treat; 2018; 29(sup1):6-8. PubMed ID: 30247936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study.
    Ortolan A; Lorenzin M; Leo G; Pampaloni F; Messina F; Doria A; Piaserico S; Ramonda R
    Dermatology; 2022; 238(5):897-903. PubMed ID: 35263743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis.
    Eviatar T; Zisman D; Gendelman O; Reitblat T; Balbir-Gurman A; Mashiach T; Almog R; Elkayam O
    Clin Exp Rheumatol; 2022 Jan; 40(1):15-23. PubMed ID: 33427613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
    McInnes IB; Sieper J; Braun J; Emery P; van der Heijde D; Isaacs JD; Dahmen G; Wollenhaupt J; Schulze-Koops H; Kogan J; Ma S; Schumacher MM; Bertolino AP; Hueber W; Tak PP
    Ann Rheum Dis; 2014 Feb; 73(2):349-56. PubMed ID: 23361084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement.
    Adami G; Idolazzi L; Benini C; Fracassi E; Carletto A; Viapiana O; Gatti D; Rossini M; Fassio A
    Reumatismo; 2023 May; 75(1):. PubMed ID: 37154254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retention rate of secukinumab in psoriatic arthritis: Real-world data results from a Spanish multicenter cohort.
    Valero-Expósito M; Martín-López M; Guillén-Astete C; Joven B; Merino-Argumanez C; Emperiale V; Campos J; Pérez A; Bachiller-Corral J
    Medicine (Baltimore); 2022 Sep; 101(36):e30444. PubMed ID: 36086678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis.
    Deodhar A; Gladman DD; McInnes IB; Spindeldreher S; Martin R; Pricop L; Porter B; Safi J; Shete A; Bruin G
    J Rheumatol; 2020 Apr; 47(4):539-547. PubMed ID: 31203228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    McInnes IB; Mease PJ; Kirkham B; Kavanaugh A; Ritchlin CT; Rahman P; van der Heijde D; Landewé R; Conaghan PG; Gottlieb AB; Richards H; Pricop L; Ligozio G; Patekar M; Mpofu S;
    Lancet; 2015 Sep; 386(9999):1137-46. PubMed ID: 26135703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis.
    Ramonda R; Lorenzin M; Chimenti MS; D'Angelo S; Marchesoni A; Selmi C; Lubrano E; Santo L; Luchetti Gentiloni MM; Atzeni F; Cauli A; Manara M; Rossini M; Foti R; Cozzi G; Scagnellato L; Ferraioli M; Carriero A; Luciano N; Ruzzon F; Fatica M; Fracassi E; Doria A; Foti R; Carletto A
    Front Immunol; 2024; 15():1435599. PubMed ID: 39076975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study.
    Kampylafka E; d'Oliveira I; Linz C; Lerchen V; Stemmler F; Simon D; Englbrecht M; Sticherling M; Rech J; Kleyer A; Schett G; Hueber AJ
    Arthritis Res Ther; 2018 Jul; 20(1):153. PubMed ID: 30053825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries.
    Michelsen B; Georgiadis S; Di Giuseppe D; Loft AG; Nissen MJ; Iannone F; Pombo-Suarez M; Mann H; Rotar Z; Eklund KK; Kvien TK; Santos MJ; Gudbjornsson B; Codreanu C; Yilmaz S; Wallman JK; Brahe CH; Möller B; Favalli EG; Sánchez-Piedra C; Nekvindova L; Tomsic M; Trokovic N; Kristianslund EK; Santos H; Löve TJ; Ionescu R; Pehlivan Y; Jones GT; van der Horst-Bruinsma I; Ørnbjerg LM; Østergaard M; Hetland ML
    Arthritis Care Res (Hoboken); 2022 Jul; 74(7):1205-1218. PubMed ID: 33460531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis.
    Kampylafka E; Tascilar K; Lerchen V; Linz C; Sokolova M; Zekovic A; Kleyer A; Simon D; Rech J; Sticherling M; Schett G; Hueber AJ
    Arthritis Res Ther; 2020 Sep; 22(1):207. PubMed ID: 32907626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.
    Buchanan V; Sullivan W; Graham C; Miles L; Jugl SM; Gunda P; Halliday A; Kirkham B
    Pharmacoeconomics; 2018 Jul; 36(7):867-878. PubMed ID: 29797187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.